Effects of glibenclamide on postprandial coagulation activation

Background and Aim: Previous data indicate that even mild postprandial hype rglycaemia in diabetic subjects, who are concerned to be in good control, a ctivates haemostasis. The aim of this study was to investigate the effect o f the oral administration of 5 mg glibenclamide on postprandial activation of coagulation in type 2 diabetics. Methods and Results: We designed a placebo controlled, randomised study. Af ter an overnight fast, each subject (n=16, age 50-68 yr.) underwent a stand ard test meal (600 Kcal: carbohydrates 40%, lipids 50%, proteins 10%) prece ded by one tablet of glibenclamide (5 mg) ol placebo. The two tests were pe rformed randomly with an interval of 7 days. Blood samples were collected a t baseline and 2 and 4 hours after the meal to measure the concentrations o f glucose, insulin, c-peptide, triglycerides as well as of d-dimers, fibrin ogen, F1.2 and TAT The postprandial levels of TAT fibrinogen, F1.2, d-dimer s, insulin, glucose and triglycerides were significantly higher compared to baseline values. Conclusions: The postprandial levels of glucose, triglycerides, fibrinogen, F1.2, TAT and d-dimers Mere lower after glibenclamide administration as co mpared to placebo, while the concentrations of insulin and c-peptide were h igher. Thus, acute administration of glibenclamide reduces the postprandial activation of coagulation. Nutr Metab Cardiovasc Dis (1999) 9: 204-207 (C) 1999, Medikal Press.